Loading…
Funds to expand commercialization and clinical trial activity.
Gelteq Ltd (Nasdaq: GELS) announced a $3.5 million strategic debt financing. The funds will be used to expand commercialization efforts and support ongoing clinical trial activities.
The financing amount totals $3.5 million. There are 4,678,300 shares in the free float.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.